Biomedicine Daily · Saturday, 3 October 2026
CBA FRONTIER INSIGHTS
Novartis Licenses Abogen's mRNA-TCE Pipeline in Deal Worth Up to $7.775 Billion
Abogen Biosciences has granted Novartis a license with option rights over its mRNA T-cell engager pipeline, taking $575 million upfront with the deal potentially reaching $7.775 billion if all options are exercised and milestones are met. Announced October 2, it ranks among the largest outbound mRNA platform licensing deals by a Chinese biotech to date, and lands amid a busy day in obesity: survodutide's NEJM results showed 9.8% weight loss at 6.0 mg over 76 weeks in type 2 diabetes, but Zealand shares fell more than 8% as analysts deemed the efficacy uncompetitive. Regulators were equally active, with the FDA approving pirtobrutinib for first-line CLL, iberdomide as the first myeloma approval based on MRD negativity, and the first therapy for Sanfilippo syndrome type A.
Clinical readouts and safety
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
Once-weekly survodutide, a glucagon receptor-GLP-1 receptor dual agonist, produced mean weight reductions of 8.2% at 3.6 mg and 9.8% at 6.0 mg over 76 weeks in 752 adults with type 2 diabetes and BMI of 27 or more, versus 3.9% with placebo. At least 5% weight loss occurred in 57.6% and 64.5% of the survodutide groups versus 35.1% on placebo, with glycated hemoglobin falling 0.9 and 0.8 percentage points. Gastrointestinal adverse events, mostly mild to moderate, occurred in 72.8% and 77.7% of survodutide recipients.
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
The GLP-1/GIP dual receptor agonist ribupatide, a weekly injectable from Kailera Therapeutics and Hengrui Pharma, produced dose-dependent weight loss of 10%, 15.1% and 20.2% at 1 mg, 2 mg and 4 mg in a Phase 2 trial of 158 Chinese women aged 18 to 40 with polyendocrine metabolic ovarian syndrome and obesity or overweight, versus 2.6% on placebo at 32 weeks. All ribupatide dose groups also showed increased menstrual frequency, while placebo cycles grew more infrequent, with no serious adverse events or discontinuations. The data suggest an incretin therapy could be developed specifically for PMOS, a condition where semaglutide and tirzepatide are used off-label without indication.
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
Survodutide, Zealand and Boehringer Ingelheim's glucagon/GLP-1 receptor dual agonist, met both co-primary endpoints in the Phase 3 SYNCHRONIZE-2 trial but produced weight loss analysts view as uncompetitive: up to 9.8% weight reduction at the highest 6 mg dose under the NEJM treatment regimen estimand at 76 weeks, versus 3.9% for placebo, and 79.3% of 775 patients lost at least 5% of body weight. About 18% discontinued due to gastrointestinal adverse events. Zealand shares fell more than 8% to $248.50. BMO analysts pointed to fat-mass effects, including 34% visceral fat loss and a 63.1% liver fat drop in SYNCHRONIZE-1, as a possible niche.
Oleeplutide Cuts Weight Up to 19.3% at 48 Weeks in Phase 3 LIGHTEN Trial
Oleeplutide delivered an average weight loss of up to 19.3% at 48 weeks in the phase 3 LIGHTEN trial, with the weight-loss curve not yet at plateau, and mean waist circumference fell by up to 16.0 cm. Nausea and vomiting occurred at average rates of 7.8% and 4.9%. The data were presented at EASD 2026.
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
In a Phase 2b trial of 149 patients with hidradenitis suppurativa, Merck's investigational anti-TL1A antibody tulisokibart hit its primary endpoint, with most patients on the high and medium doses achieving at least 50% reduction in skin abscesses and inflammatory nodules. Analysts called the placebo-corrected efficacy potentially differentiated versus Humira and noted the drug's once-every-four-weeks dosing interval. Serious side effects were infrequent and there were no serious or opportunistic infections, setting up a push into late-stage development.
Pfizer’s eczema drug clears skin in mid-stage trial
Pfizer's trispecific antibody tilrekimig, which blocks IL-4, IL-13 and TSLP, beat placebo on skin clearance in a Phase 2 trial in moderate to severe atopic dermatitis. After 16 weeks, 63% of patients on 450 mg every two weeks reached EASI-75 versus 20% on placebo; in Stage 2, 48% to 61% across monthly doses reached EASI-75 versus 9% on placebo. Pfizer has moved the drug into Phase 3 testing, including a head-to-head trial against Dupixent.
Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer
The pan-RAS inhibitor daraxonrasib shrank tumors in more than 30% of patients with previously treated RAS-mutant non-small cell lung cancer. The drug recently earned approval in pancreatic cancer, and these findings support an ongoing phase III trial in lung cancer.
[ 18 F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [ 18 F]FDG PET/CT and Conventional Imaging
The CD70-targeting radiotracer [18F]RCCB6 PET/CT detected metastases in clear-cell renal cell carcinoma with 94.2% sensitivity, 80% specificity and 98.3% positive predictive value across 1,221 assessable extrarenal lesions. In head-to-head comparison it beat [18F]FDG PET/CT (sensitivity 90.5% vs 41.1%) and conventional imaging (90.8% vs 75.1%), and tracer uptake correlated with CD70 expression (r = 0.843). Findings changed clinical management in 58.7% of the 150 patients imaged.
Lanreotide for Advanced Pheochromocytoma and Paraganglioma: Results of a Multicenter Phase II Trial
Lanreotide depot/autogel 120 mg every 4 weeks showed antiproliferative activity in 18 patients with advanced or metastatic pheochromocytomas and paragangliomas, most of them (78%) carrying SDHx mutations. Disease stabilization occurred in 11 of 13 patients (85%) at about 1 year, with two partial responses and a median tumor growth rate of 0.00124/day (doubling time 559 days), consistent with a median PFS of at least 2 years. Treatment was well tolerated, with no discontinuations due to toxicity. The findings support somatostatin analogues as an option for SSTR-positive PPGL before escalating to more aggressive treatments.
Regulatory and policy
In Regulatory First, Myeloma Drug Approved Based on MRD Negativity
The FDA has approved iberdomide for multiple myeloma on the basis of minimal residual disease negativity, the first approval for the disease to use that endpoint. Iberdomide also represents a new generation of targeted protein degraders, with several more potent cereblon E3 ligase modulators already in clinical development.
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
FDA approved Eli Lilly's pirtobrutinib (Jaypirca) on October 2, 2026 for adults with previously untreated CLL or SLL without 17p deletion. In the BRUIN CLL-313 trial of 282 patients randomized to pirtobrutinib or bendamustine plus rituximab, median PFS was not estimable with pirtobrutinib versus 33.5 months in the control arm (hazard ratio 0.20, p<0.0001) at a median follow-up of 28 months. The recommended dose is 200 mg orally once daily until progression or unacceptable toxicity.
FDA Approves Ultragenyx Gene Therapy Fayuvi for Children with MPS IIIA
The FDA has approved Fayuvi (rebisufligene etisparvovec), a gene therapy developed by Ultragenyx Pharmaceutical, making it the first FDA-approved therapy for children with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The rare inherited disease progressively damages the brain and nervous system, causing children to gradually lose cognitive, speech and other developmental abilities over time.
China CDE Releases "Pioneer Program" Pilot Plan for New Approach Methodologies
China's Center for Drug Evaluation, with approval from the National Medical Products Administration, has issued the pilot "Pioneer Program" for advancing New Approach Methodologies (NAMs), including organoids and organ-on-chip systems. The plan, notice number 46 of 2026 dated September 30, aims to support research, validation and application of these methods in drug development and took effect upon publication. Companies developing NAMs can now look to the pilot plan for regulatory adoption pathways.
Roche files BTK inhibitor fenebrutinib for multiple sclerosis and wins FDA priority review
Roche has submitted its BTK inhibitor fenebrutinib for marketing approval in multiple sclerosis and received priority review. Against teriflunomide, fenebrutinib cut annualized relapse rates in RMS by 51.1% and 58.5%, and versus Ocrevus it reduced risk of progression in PPMS by 12%. If approved, it would be the first BTK inhibitor cleared for both RMS and PPMS, offering a new option for the 1 million US multiple sclerosis patients.
FDA puts Shengnuo Biology's Chengdu plant on Import Alert 66-40 as states squeeze GLP-1 compounders
FDA placed Chengdu Shengnuo Pharmaceutical, a wholly owned subsidiary of the Shanghai STAR-listed peptide maker Shengnuo Biology, on Import Alert 66-40 on September 19, without first issuing a warning letter, meaning its products can be detained at US customs without inspection. The company disclosed the move on September 22. The action comes as US federal enforcers penalize a large Houston compounding pharmacy for GLP-1 weight-loss drugs and attorneys general from 20 states jointly press for tighter controls on GLP-1 compounders.
FDA approves first drug to improve functional capacity and symptoms in children with rare inherited heart condition
The FDA approved Camzyos (mavacamten) as the first treatment to improve functional capacity and symptoms in children with symptomatic obstructive hypertrophic cardiomyopathy, extending approval to pediatric patients weighing at least 30 kg, after adult approval in 2022. Efficacy was supported by the phase 3 SCOUT-HCM trial in 44 patients aged 12-18, where once-daily dosing for 28 weeks significantly reduced the Valsalva LVOT gradient versus placebo. The drug carries a boxed warning for heart failure risk and is available only through the Camzyos REMS program.
Transparency Makes Modern Regulatory Science Stronger — FDA’s Transparency Roadmap
The FDA has released a Transparency Roadmap covering FY26 milestones and FY27 priorities, aiming to maximize disclosure of its regulatory reasoning. A centerpiece is its complete response letter disclosure initiative, launched in 2025 with more than 200 letters covering applications submitted between 2020 and 2024, after a 2015 internal analysis found 85 percent of the FDA's safety and efficacy concerns went unmentioned in sponsors' public announcements of non-approvals. The agency also plans rulemaking to disclose the fact of submission of NDAs, BLAs and ANDAs, and is encouraging sponsors to make IND filings public, as about 96 percent of novel drug or biologic filings are already disclosed.
White House Prepares to Bring Production of 86 Critical Drugs Back to US
The White House Office of Management and Budget is surveying generic drug manufacturing capacity in the US and nearby regions as a step toward moving production of 86 critical medicines back to the US within 18 months. The aim is to cut dependence on active pharmaceutical ingredients from China and other countries. A June 2026 Council on Foreign Relations report said China controls about 94% of global amoxicillin API or key starting materials.
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
The FDA issued a run of oncology and hematology approvals from July 31 to October 2, 2026. They include pirtobrutinib (Jaypirca, Eli Lilly) for previously untreated CLL or SLL without 17p deletion on October 2, belzutifan plus lenvatinib for advanced clear-cell renal cell carcinoma on September 24, lirafugratinib (Lyrfigtu, Elevar) for FGFR2-rearranged cholangiocarcinoma on September 23, imlunestrant plus abemaciclib for ESR1-mutated breast cancer on September 18, and daraxonrasib (RASONQUE, Revolution Medicines) for metastatic pancreatic adenocarcinoma on August 26. Accelerated approvals in the batch cover sevabertinib for HER2-mutated NSCLC, camizestrant for ESR1-mutated breast cancer, iberdomide for multiple myeloma, and vusolimogene oderparepvec plus nivolumab for melanoma.
FDA Adverse Event Monitoring System (AEMS) Electronic Submissions
FDA is implementing the Adverse Event Monitoring System (AEMS), formerly FAERS, to consolidate reporting across all FDA-regulated product categories, with AI-based redaction, enhanced analytics and cross-product surveillance. From October 1, 2026, postmarketing individual case safety reports for human drugs, biologics and drug- or biologic-led combination products submitted via ESG NextGen must use E2B(R3) data standards, a six-month extension of the prior timeline; E2B(R2) remains accepted through September 30, 2026. Electronic submission of premarketing IND safety reports in E2B(R3) format became mandatory on April 1, 2026 for commercial IND sponsors using database-to-database transmission.
Industry and deals
Abogen Biosciences Licenses mRNA-TCE Pipeline to Novartis in Deal Up to $7.775 Billion
Abogen Biosciences has granted Novartis an RNA therapy license with option rights covering its mRNA-TCE pipeline. Abogen receives $575 million upfront, and the deal could reach $7.775 billion if all options are exercised and milestones are met. Announced on October 2, it ranks among the largest outbound mRNA platform licensing deals by a Chinese biotech to date.
Zealand Pharma petrelintide shows 10.7% weight loss at 42 weeks as three Phase III trials begin
Zealand Pharma published ZUPREME-1 data for its amylin analogue petrelintide in The Lancet Diabetes and Endocrinology on September 30, with a simultaneous oral presentation at the 62nd EASD annual meeting. The once-weekly subcutaneous injection achieved up to 10.7% weight loss at 42 weeks as monotherapy, with gastrointestinal side effects close to placebo levels. Three global Phase III registration studies were launched eight days earlier.
Research papers
Population-scale immune multiome atlas reveals regulatory disease mechanisms.
Simultaneous single-nucleus profiling of chromatin accessibility and gene expression in 10 million peripheral blood mononuclear cells from 1,108 Finnish individuals yields 51,083 cis-expression QTLs, 338,100 cis-chromatin accessibility QTLs and 593,765 peak-gene links. Variants completing chromatin-to-expression cascades show twice the disease colocalization of chromatin-only effects, and massively parallel reporter assays validate 10,428 fine-mapped QTLs. The atlas supplies testable hypotheses for over half of immune disease associations and explains why disease variants preferentially target evolutionarily constrained genes through regulatory buffering at the chromatin-to-expression interface.
CD3-engaging bispecific antibodies convert human regulatory T cells into cytotoxic effectors
CD3-engaging bispecific T cell engagers convert human FOXP3+ regulatory T cells into an AP-1-imprinted hybrid cytotoxic state that contributes to tumor clearance. In newly diagnosed multiple myeloma patients treated with BTCE-based induction in the phase 2 GMMG-HD10/DSMM-XX/MajesTEC-5 trial, single-cell sequencing showed Tregs expressing GZMA, GNLY and NKG7, and in vitro BTCE-exposed Tregs killed tumor cells in a target- and dose-dependent manner. IMiDs amplified and reshaped this cytotoxic program, supporting BTCE-IMiD combination regimens.
medicalxpress.comDiscovery explains how immune cells target DNA mutations to improve antibodies
Two histone-reader proteins, MLLT1 and MLLT3, determine where the antibody-mutating enzyme AID acts in B cells by recognizing specific histone marks and concentrating AID into condensates near target genes. Genome regions with high MLLT1 and MLLT3 levels matched AID mutation sites in animal models, humans and lymphoma cells, and removing both proteins virtually abolished antibody diversification and AID-induced mutations. Inhibiting MLLT1 and MLLT3 reduced AID-dependent mutations and cancer-associated chromosomal translocations in experimental models, pointing to possible therapeutic targets in B-cell cancers.
Tumor-Secreted ADAMTSL4 Activates Latent TGFβ1 to Drive Cancer Cachexia
Tumor-secreted ADAMTSL4 emerges as a circulating driver of cancer cachexia, linked to body weight loss in preclinical models and patients with colorectal and lung cancers. In mice, Adamtsl4 overexpression made tumors cachexia-inducing, while its deletion spared fat and muscle and reduced cachexia severity. ADAMTSL4 activates latent TGFβ1 by engaging its latency-associated peptide, and blocking this axis reduced wasting and muscle fibrosis.
Cell study points to gut microbial metabolites, not just composition, as predictors of CAR-T efficacy
Gut microbial metabolites, not just microbiota composition, may determine CAR-T therapy outcomes. Analysis of 129 CAR-T patients across three German centers, plus single-cell transcriptomic and animal experiments, identified immunomodulatory metabolites with opposing effects on CAR-T efficacy. The work argues prediction of CAR-T response should shift toward microbial metabolic function.
medicalxpress.comHow loss of the critical tumor suppressor p53 enables mutant cells to expand through normal tissue
Loss of p53 lets mutant clones expand through normal tissue by reorganizing Wnt signaling into a persistent radial gradient, low at the clone edge and high at its center, rather than by simply raising overall Wnt activity. In mouse skin, clones with this gradient expanded efficiently while clones with uniformly higher Wnt activity expanded less. The work maps how p53, acting through Sfrp1, Lrp1 and Usp22, shifts epidermal progenitor cells toward self-renewal and away from differentiation, enabling clonal expansion long before tumors form.
Structural mechanism governing the directionality of bridge recombination.
IS621 recombinase-bridge RNA complexes mediate excision less efficiently than insertion, and cryo-EM structures explain why: excision substrates adopt linear conformations forming an X-shaped structure, unlike the bent U-shape of insertion, which reduces top-strand exchange efficiency and explains the natural bias toward insertion. Both reactions are tuned by base pairing between bRNA handshake-guide dinucleotides and top strands. The work clarifies the full IS110 transposition cycle and guides design of programmable bridge-editing tools.
A cholinergic hub in the nucleus accumbens gates opioid-reward learning.
Blocking opioid receptors specifically on accumbal cholinergic interneurons abolishes morphine conditioned place preference in mice, even though dopamine increases in the nucleus accumbens are unaltered. The study used naloxoneDART, a cell-type-specific naloxone analogue, which prevented morphine-induced acetylcholine reductions while leaving hyperlocomotion, sensitization and acute analgesia intact. The work identifies a cholinergic gate for opioid-reward learning separable from analgesia.
Senescent-Like Neutrophils Shape Angiogenic Immunosuppressive Niches in Colorectal Cancer Liver Metastasis
A terminally differentiated protumor neutrophil subset, TAN1, marked by a glycolysis signature and senescent phenotype, is enriched in colorectal cancer liver metastasis and linked to poor prognosis. Single-cell and spatial-enhanced-resolution-omics sequencing show TAN1 arises from other tumor-associated neutrophil subsets via BHLHE40 upregulation driven by glucose deprivation, and promotes angiogenesis through VEGFA while recruiting immunosuppressive macrophages via CCL3L1-CCR1 signaling. Neutrophil-specific Bhlhe40 knockout in mice boosted antitumor immunity and suppressed tumor growth, pointing to a neutrophil-specific therapeutic target.
Tissue resident CD4+ memory T-cells mark response to immune checkpoint inhibition in high-grade glioma
Tissue-resident CD4+ memory T cells mark which high-grade gliomas respond to combined PD-1 and CTLA-4 inhibition. In a syngeneic hypermutated glioma model, response involved clonal expansion of tumor-reactive cytotoxic T cells and infiltration of CXCR6+ CD4+ Trm cells, with CD4 stem-like memory cells showing interferon responses rather than exhaustion. In IDH1 wildtype glioblastoma patients treated with neoadjuvant pembrolizumab, CD4+ Trm association with prolonged overall survival was confirmed.
Human Cortico-Striatal Assembloids Reveal SCN2A Paradox: Weaker Connections but More Excitable Neurons
Human cortico-striatal assembloids show how autism-linked loss-of-function mutations in SCN2A disrupt connections between brain regions. SCN2A protein-truncating mutations reduced long-range cortical axon projections, lowered striatal dendritic spine density and weakened excitatory synaptic transmission, yet increased neuronal intrinsic excitability and spontaneous network firing. The work resolves how loss of a single ion channel gene disturbs wiring across human brain regions.
Language and executive decline in ALS map to distinct frontal cortex cell phenotypes
ALS cognitive heterogeneity traces to distinct cellular phenotypes in frontal cortex: executive dysfunction associates with reduced mitochondrial and synaptic activity in deep-layer neurons, while language deficits associate with diffuse glial-vascular dysregulation. About half of ALS patients show non-motor involvement, and about 35% have mild cognitive impairment including language deficits and executive decline. The work indicates different brain-region-specific cellular mechanisms, rather than one shared mechanism, underlie the clinical spectrum.
The early RNA decay factor ZC3H18 directs first intron splicing.
ZC3H18, known as an early RNA decay factor recruiting the NEXT complex through the CBC-ARS2 axis, also stimulates first intron splicing genome wide by interacting with the splicing factors PRPF40A, PRP4K, and FNBP4. Disruption of the CBC-ARS2-ZC3H18 axis corrupts first intron splicing, and splicing factor binding to ZC3H18 is mutually exclusive with NEXT binding. The findings explain cap-stimulated first intron splicing as displacement of NEXT by splicing factors, routing nascent RNA to splicing rather than decay.
Sustained Ion Imbalances Enhance Ferroptosis
Sustained imbalances in sodium, potassium and chloride ions drive ferroptosis across chemo-resistant cancer cell lines of different origins. Clinically approved modulators of CFTR and Kv7.2 inhibit ferroptosis independent of ion channel expression, and combining the ferroptosis inducer salinomycin with digoxin, a Na+/K+ ATPase inhibitor, enhanced ferroptotic cell death in vitro and reduced tumor growth in vivo beyond either agent alone. The work points to ion homeostasis as a broadly applicable ferroptosis target and to repurposing approved drugs for ferroptosis-associated diseases.
Spatiotemporal clonal architecture of the newborn mouse forebrain
Clonal barcoding across the newborn mouse forebrain shows that glutamatergic neurons and astrocytes remain locally derived, while widely dispersed GABAergic lineages link neurons with oligodendrocyte precursor cells. The work establishes spatiotemporal clonal architecture as a framework for forebrain development. It revises the view of how cell types in the forebrain are related by lineage.
Methods and resources
Functional Deorphanization of Tumor-reactive TCRs Uncovers a Landscape of Shared, Immune Dominant Antigens across Cancers
The TWISTAR platform deorphanizes single-cell-derived TCRs against tumor transcriptomes and directly validates TCR engagement, so it recovers only functionally immunogenic antigens. Applied to melanoma, breast, and hepatocellular carcinoma patients responding to immune checkpoint blockade, it shows tumor-reactive TCRs recognize many targets beyond neoantigens, including peptides from unannotated coding sequences and novel transcripts. Many antigens are shared across patients and cancer types, with multiple T cell clones converging on a few immune dominant epitopes, supporting pan-cancer vaccine development.
Genome-wide mapping of endogenous topoisomerase cleavage complexes reveals TOP1 at the interface of DNA topological regulation and genome instability
Protein-DNA adduct immunoprecipitation followed by sequencing (pDAIP-seq) detects endogenous topoisomerase cleavage complexes genome-wide without stabilization by topoisomerase poisons, revealing that camptothecin, required by prior TOP1cc profiling methods, substantially alters the genomic distribution of TOP1cc. Endogenous TOP1cc were reduced by transcriptional suppression and increased by TOP2A depletion, and their positioning was largely specified by local DNA sequence context. The method also maps TOP2cc, TOP3cc and SPO11-DNA intermediates in mouse testis and identifies endogenous TOP1cc as a potential major source of spontaneous DNA breaks in human cells.
medicalxpress.comPET scans reveal alpha cancer therapy isotope with new algorithm in first human test
A new image-reconstruction algorithm, TOF-CGI (time-of-flight cascade gamma-ray imaging), lets standard PET scanners image the alpha-emitting therapy isotope actinium-225 by exploiting its gamma-ray pairs, a task PET was long assumed unable to perform. In a first-in-human pilot with one prostate cancer patient, TOF-CGI PET identified the same tumors seen on diagnostic PET and detected more actinium-225 decays than SPECT. The method could open a third imaging route for targeted alpha therapy.
Disease relevance and replicability of deep learning gene expression prediction
Deep learning models that predict gene expression from DNA sequence owe their high overall correlation mostly to capturing whether genes are on or off, not to disease-relevant changes in expression among active genes; performance rises with how bimodal a gene's expression distribution is. The authors also found inconsistencies between published code and reported performance, and conclude that personalized genomic prediction in disease remains far from solved.
A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response
MutationProjector, a foundation model pretrained on genomic alterations from more than 30,000 tumors, reconstructs held-out mutations and predicts immunotherapy or chemotherapy resistance across multiple cancer types, achieving or exceeding state-of-the-art performance in all tested contexts. It also identifies biomarkers including KMT2D mutation for immunotherapy sensitivity and joint SMARCA4 and STK11 alteration for resistance. It offers a unifying framework linking tumor genotypes to mechanisms and therapeutic outcomes.
Cargo size matters when designing lipid nanoparticles for delivery of large gene editors.
Screening ionizable lipids with a gene-editor-sized RNA yielded LC-1, a lipid that forms a structure enhancing endosomal escape of large editor mRNAs. Lipid nanoparticles built on LC-1 achieved efficient genome editing in the liver, lung and brain of mice. The work points to cargo size as a design criterion for lipid nanoparticles delivering large gene editors.
Applying AlphaGenome Variant Impact for SNV Prioritization
Empirical thresholds linking the AlphaGenome Variant Impact (AVI) quantile rank to clinical variant classifications are now established: a Youden-optimal cutoff of 0.9938 separates ClinVar pathogenic/likely pathogenic SNVs from benign ones, with broadly consistent cutoffs across molecular consequence classes and gene-disease groups. Applying the cutoff to 24,989 variants of uncertain significance flagged 11,357 (45.45%) with predicted functional effects comparable to pathogenic variants. In steroid-dependent asthma fine-mapping, AVI_QUANTILE showed little correspondence with SuSiE posterior inclusion probabilities, indicating AlphaGenome predictions capture information distinct from statistical fine-mapping.
Identifying, phasing, and structurally annotating sex chromosomes for genome assemblies using CBS-tools
CBS-tools is a k-mer based pipeline using whole-genome sequencing of a few sex-identified isolates to identify sex chromosomes in genome assemblies. It predicted the correct heterogametic sex in all 31 species tested from public datasets, verified and corrected phasing of sex chromosomes between haplotypes, and delimited the sex-determination region boundary via an interactive web platform. It works for both unexplored and well-examined sex chromosome systems.
Opinion and commentary
medicalxpress.comHow sex chromosomes influence lifelong health beyond determining biological sex
A review published in Science, co-led by Dr. Dan Theodorescu of the University of Arizona Cancer Center and Dr. Dena B. Dubal of UC San Francisco, argues that X and Y chromosome genes shape disease risk, progression and treatment response in aging, cancer, neurological conditions, immunity and cardiometabolic disease, beyond the effects of sex hormones. The review links loss of the X chromosome in women to higher leukemia risk and loss of the Y in men to cancers, heart disease, severe infections and Alzheimer's disease. It grew out of the 2025 National Institute on Aging Workshop and calls for sex-aware clinical trial design and sex-tailored diagnostics and treatment.
Researchers are discovering more infections that can cause cancer
An IARC study published in The Lancet Oncology estimates that infectious pathogens accounted for 12% of new cancer cases worldwide in 2024, about 2.3 million cases. A Reddit discussion of the study's pathogen list turned to whether COVID might also be oncogenic, with commenters suggesting indirect mechanisms such as EBV reactivation, autoimmunity and inflammation. IARC's figures and pathogen list still need verification against the journal paper, and the COVID-cancer link remains speculation by the community.
[Policy Review] Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer
Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer issued recommendations on reporting health-related quality of life in randomised clinical trials of adjuvant systemic therapy after locoregional cancer treatment. They argue that because many adjuvant therapies yield small gains in relapse-free or overall survival, side-effects and their effect on patient functioning and HRQOL must be reported to inform clinical decision making.
biocentury.comChina biopharma still faces a long road to globalization
Franck Le Deu of KerZheng Ventures argues that Chinese biopharma companies are unlikely to become conventional global competitors by 2030, despite strong science, because the U.S. dominates the profit pool, taking about 53% of world prescription-medicine sales in 2025 and 74% of sales of medicines launched in 2020-24. He weighs Pfizer's Innovent Biologics collaboration worth up to $10.5 billion and China's Five-Year Plan targets, including first-in-class drugs reaching a quarter of the global total and five products exceeding $1 billion in sales by 2030, against barriers like CFIUS and geopolitics. He suggests few will succeed in the Western model, and alternative paths such as affordable innovation outside the U.S. market may define globalization instead.
In brief
- Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.Nat Med
- Evolutionary dynamics of the insertion sequence IS6110 in the Mycobacterium tuberculosis complexbiorxiv.org
- Genetic risk and inflammatory signaling converge on cell type-specific regulatory programs in type 1 diabetesbiorxiv.org
- The Smac mimetic drug Xevinapant sensitizes triple negative breast cancer to radiotherapy-induced cell death in a TNFα dependent mannerbiorxiv.org
- Retraction Note: Ribosomal frameshifting in the CCR5 mRNA is regulated by miRNAs and the NMD pathwaynature.com
- Circadian gene-network distortion in high-risk neuroblastoma across multiple biological reference contextsbiorxiv.org
- Alcohol Use Disorder and Smoking-Associated Molecular Alterations in Human Prefrontal Cortex in Single Nucleus (sn) RNA-Seqbiorxiv.org
Also today
23 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
Clinicalretatrutide · giredestrant · orforglipron · eloralintide+Zepbound …12 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
- retatrutideUpdateRetatrutide produced mean weight losses of 17.6% at 4 mg, 23.7% at 9 mg and 25.0% at 12 mg over 80 weeks in 2339 randomized patients with obesity but without diabetes, versus 3.9% with placebo (P<0.001). Subgroups with knee osteoarthritis saw pain scores fall by 3.2 to 3.6 versus 1.9 on placebo, and patients with obstructive sleep apnea had 22.9 to 34.3 fewer events per hour versus 9.9. The most common adverse events were gastrointestinal.
- giredestrantUpdateAdding the oral SERD giredestrant to everolimus improved progression-free survival in ER-positive, HER-2-negative advanced breast cancer after prior CDK 4/6 inhibitor treatment. In the phase 3 evERA study of 373 patients, median PFS rose from 5.5 to 8.8 months overall (44% risk reduction) and from 5.5 to 10 months in the roughly 55% with ESR1-mutant tumors (63% risk reduction). It offers an all-oral option where post-CDK 4/6 choices are limited.
- orforglipronUpdateOrforglipron, an oral non-peptide GLP-1 receptor agonist, was non-inferior to insulin glargine for four-component major adverse cardiovascular events in 2749 adults with type 2 diabetes at increased cardiovascular risk: MACE-4 occurred in 57 (4·2%) of 1358 orforglipron participants versus 67 (5·0%) of 1343 insulin glargine participants (HR 0·84; 95% CI 0·59-1·20) over a median follow-up of 2 years. Clinically significant or severe hypoglycaemia was less frequent with orforglipron (93, 6·8%) than insulin glargine (260, 19·2%), while gastrointestinal adverse events were more frequent (62·1% vs 14·2%). The results establish cardiovascular safety for a non-peptide GLP-1 receptor agonist, a class not previously studied for this outcome.
- eloralintide+ZepboundUpdateEloralintide plus tirzepatide (Zepbound) produced 23.3% weight loss at the highest dose after 48 weeks, or 20.3% placebo-adjusted, in Phase IIb obese patients with Type II diabetes. The Eli Lilly combination beat both Novo's CagriSema and Lilly's own triple agonist retatrutide, in a population where weight loss is harder to show than in non-diabetic obesity.
- Effects of semaglutide on kidney disease in type 2 diabetesUpdateSemaglutide's kidney protection in type 2 diabetes and chronic kidney disease may work through reduced vascular resistance and prevention of fibrosis. In a 52-week randomized trial of 106 participants, semaglutide 1 mg weekly lowered renal artery resistive index and stabilized the apparent diffusion coefficient versus placebo, while MRI coprimary outcomes (R2* oxygenation, perfusion, T1 inflammation) were unchanged. Paired biopsies showed pronounced effects on glomerular endothelial cells with fewer nearby immune cells.
- Liver Cancer Awareness MonthUpdate
- sofosbuvir-velpatasvirUpdateEight weeks of sofosbuvir-velpatasvir cleared chronic hepatitis C as well as the standard 12 weeks in treatment-naive, non-cirrhotic patients. In the per-protocol analysis, SVR12 was achieved by 410 of 415 participants with 8 weeks and 397 of 401 with 12 weeks, meeting the non-inferiority margin. The intention-to-treat analysis also showed non-inferiority, with no drug-related serious adverse events.
- FoundayoUpdate
- Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor dataUpdate
- Insights into the potential of nuvisertib plus momelotinib in patients with myelofibrosis and anemiaUpdate
- Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshakenUpdate
- Taiho scores phase 3 win with oral cancer combo for AMLUpdate
Deals and financingNovartis wagers almost $8B on a Chinese biotech’s RNA drugs · Merck Pays $400 Million Upfront for Global Rights to Sipurui's Oral KRAS G12D Inhibitor SPR2015 · Sanofi Pays Regeneron $1 Billion Upfront for Four Long · Chinese Oral Weight …7 ▾▴
Licensing, M&A and financing that did not make the daily.
- Novartis wagers almost $8B on a Chinese biotech’s RNA drugsUpdateNovartis will pay Abogen Biosciences $575 million up front in a deal worth as much as $7.8 billion, gaining access to the Chinese biotech's mRNA-encoded drugmaking technology and an option to license ABO2203, a T cell engager targeting CD3 and CD19 being studied in relapsed or refractory B-cell non-Hodgkin lymphoma. Abogen is eligible for up to $7.2 billion in milestone payments, and Novartis could license additional programs. The deal follows a series of Novartis trial failures in September, including three deaths in a paused autoimmune CAR-T trial.
- Merck Pays $400 Million Upfront for Global Rights to Sipurui's Oral KRAS G12D Inhibitor SPR2015UpdateOn September 28, Sipurui and Merck (MSD) announced a global exclusive license for SPR2015, an investigational oral KRAS G12D (ON) inhibitor. Merck gains worldwide development, manufacturing and commercialization rights, while Sipurui receives a $400 million upfront payment and is eligible for development and commercialization milestone payments, with the potential total deal value reaching $2.13 billion. The $400 million upfront is a record for a Chinese preclinical-stage business development deal on an asset that has no human data yet.
- Sanofi Pays Regeneron $1 Billion Upfront for Four LongUpdateSanofi has licensed four early-stage long-acting antibodies from Regeneron, all targeting the type 2 inflammation pathway, for a $1 billion upfront payment. All four assets were developed in-house by Regeneron. The deal is framed as new CEO Belén Garijo's first major bet for the post-Dupixent era; Sanofi's European shares rose about 2% on the news.
- Chinese Oral WeightUpdateAn oral weight-loss drug developed in China has been licensed to an overseas partner in a deal worth up to $2.6 billion in total. The agreement includes $300 million upfront plus payments tied to development, regulatory and commercial milestones, and the licensor is also eligible for sales royalties. The parties and drug name were not disclosed in the material.
- Varda Space IndustriesUpdate
- TriGemX BioUpdate
- Revier TherapeuticsUpdate
OtherCamzyos · Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin · FDA CDER/CBER · Non4 ▾▴
Everything else with a concrete event that did not make the daily.
- CamzyosUpdateFDA
- Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Update
- FDA CDER/CBERUpdateFDA
- NonUpdateFDA